SS-31 10mg Dosage Protocol

1. Preparation and Measurement

SS-31 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

Preparation

1. Draw 2mL of bacteriostatic water using sterile equipment.
2. Let the liquid run slowly down the inside wall of the vial.
3. Gently swirl until dissolved. Do not shake.
4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Vial estimate: One 10mg vial contains approximately 2 administrations at the first listed amount; later rows exceed one vial's total content.

Practical Notes

• The table applies only to this vial prepared with exactly 2mL.
• An asterisk marks measurements above 1mL, which exceed the capacity of a standard 1mL U-100 syringe.
• Some later entries also exceed the total material in one vial and are shown only to preserve the documented schedule comparison.
• Record the amount, date, and preparation used.

3. Supplies Needed

• SS-31 10mg vial.
• 2mL of bacteriostatic water per vial.
• Sterile U-100 syringes.
• Alcohol swabs.
• Sharps container.

4. Storage and Handling

• Keep unopened vials cool, dry, dark, and protected from moisture.
• After preparation, refrigerate at 2-8 degrees C.
• Protect from light and avoid repeated freeze-thaw cycles.
• Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

SS-31, also studied as elamipretide, targets mitochondrial membranes and has been evaluated in preclinical models and human trials. Clinical results have been mixed, and trial formulations cannot be assumed equivalent to research material.

SS-31 is not approved for general therapeutic use. The table records a circulated convention and is not a clinical recommendation.

Primary Research and Regulatory References

1. Elamipretide MMPOWER-3 clinical trial
2. Elamipretide dose-escalation study
3. SS-31 mitochondrial mechanism study